FDA approves Reyataz capsules for treating HIV-1 infection
Bristol-Myers Squibb Co.’s Reyataz (atazanavir) capsule (300 mg) has been approved by the U.S. Food and Drug Administration for use in combination with ritonavir (100 mg) to treat HIV-1 infection. On the basis of results of the year-long trial which show that atazanavir was as effective as lopinavir along with ritonavir in achieving virologic response in adult patients who received tenofovir and emtricitabine (300 mg/200 mg once daily) therapy simultaneously.
- FDA nod to Tibotec’s PREZISTA for treating HIV-1 infection
- Novartis vaccine shows stronger immune response against meningococcal strains
- Inverness Medical launches Determine HIV-1/2 Ag/Ab Combo test for HIV diagnosis
- FDA approves Lev’s Cinryze™ to treat HAE attacks
